

1 **Factors affecting antenatal corticosteroid use in low- and middle-income countries: facility**
2 **characteristics, structural readiness, and past performance of CEmONC signal functions**

3

4 **Author information**

5 Wen-Chien Yang (0000-0001-8206-1496)^{1*}; Catherine Arsenault (0000-0003-2410-3015)¹;

6 Victoria Y. Fan (0000-0001-7755-9425)²; Nazia Binte Ali (0000-0001-5010-9563)³;

7 Fadhlun Mohamed Alwy Al-beity (0000-0003-2416-6876)⁴; Emily R. Smith (0000-0001-5715-
8 9459)^{1, 5}

9

10 1. Department of Global Health, Milken Institute School of Public Health, The George

11 Washington University, Washington, DC, USA

12 2. Center for Global Development, Washington, DC, USA

13 3. Department of Global Health and Population, Harvard T.H. Chan School of Public Health,
14 Boston, Massachusetts, USA

15 4. Muhimbili University of Health and Allied Science, Dar es Salaam, Tanzania

16 5. Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, The
17 George Washington University, Washington, DC, USA

18

19

20 Word count: 3062

21 Abstract word count: 300

22 Number of figures and tables: 4

23

24 *Corresponding Author: Wen-Chien Yang, MD, MPH

25 Address: 950 New Hampshire Ave, NW, Washington DC, 20037

26 Telephone: 617-794-2209

27 Email: wenchienyang@gwmail.gwu.edu

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47 **ABSTRACT**

48 **Background**

49 Antenatal corticosteroids (ACS) utilization is disproportionately limited in low- and middle-
50 income countries where most global preterm newborns who could benefit from this intervention
51 are born. Understanding the factors affecting ACS use is crucial for improving its uptake. This
52 study aimed to investigate facility-level factors associated with ACS use in low-resource
53 countries.

54 **Methods**

55 We used data from ten Service Provision Assessment surveys across nine countries. We
56 restricted the sample to facilities that provided delivery services. Our primary outcome was
57 recent ACS use, defined as having administered ACS within the past three months before the
58 survey. We conducted mixed-effect log binomial regressions, with country as a fixed effect and
59 sub-national regions as random intercepts, to explore the association between recent ACS use
60 and facility characteristics, injectable corticosteroids and ultrasound availability, facility
61 structural readiness, and past performance of nine Comprehensive Emergency Obstetric and
62 Newborn Care (CEmONC) signal functions.

63 **Results**

64 This study included 6183 facilities from nine countries. Across eight countries with nationally
65 representative data, only 22.7% (median, range 4.0% to 27.4%) of facilities that provided
66 delivery services had used ACS recently. Urban facilities had a 21% higher likelihood of recent
67 ACS use (95% CI 6%–38%) than rural facilities. Corticosteroid availability was associated with
68 a 14% higher likelihood of recent ACS use (95% CI 1%–29%). Facilities in the highest readiness
69 tertile were more likely to have recent ACS use than those in the lowest (RR 1.91, 95% CI 1.58–

70 2.30). Each CEmONC signal function, except for assisted vaginal deliveries, was significantly
71 associated with recent ACS use, with neonatal resuscitation having the largest effect (RR 2.62,
72 95% CI 1.93–3.55).

73 **Conclusion**

74 Facilities that had performed CEmONC services were more likely to administer ACS,
75 highlighting the importance of provider knowledge, skills, and competence in managing obstetric
76 and newborn emergencies for effective ACS provision.

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93 INTRODUCTION

94 Administering antenatal corticosteroids (ACS) to pregnant women with a high likelihood of
95 preterm labor at gestational age (GA) 24 to 34 weeks is recommended by the World Health
96 Organization (WHO) and major medical associations.(1-4) By accelerating fetal lung maturity,
97 this intervention effectively reduces neonatal mortality and morbidity, particularly respiratory
98 complications.(5) ACS use has been encouraged in low- and middle-income countries (LMICs),
99 where 80% of preterm births occur globally.(6) However, its uptake remains limited in these
100 countries. The WHO Born Too Soon report suggested prioritizing existing highly effective
101 interventions, including ACS.(7) The International Federation of Gynecology and Obstetrics also
102 listed ACS use among its PremPrep-5 initiative of effective and low-cost interventions to
103 improve preterm outcomes.(8) Therefore, a thorough understanding of factors associated with
104 low ACS use in LMICs is urgently needed.

105 Factors affecting ACS use in low-resource countries are complex.(9) These factors can be
106 primarily grouped into several levels. At the national level, guidelines and policies on ACS use
107 are fundamental. Previous studies have identified limited, unclear, or inconsistent national
108 guidelines as major obstacles.(9-12) The 2023 WHO Model List of Essential Medicines includes
109 dexamethasone, one of the two antenatal corticosteroids, under medicines for reproductive health
110 and perinatal care.(13) A study assessing barriers to ACS use found that the absence of ACS
111 from National Essential Medicines Lists was a significant barrier in half of the twelve African
112 and Asian countries examined.(11) Another policy analysis for seven sub-Saharan countries
113 showed that although most countries included ACS use in their national protocols, details on
114 accurate GA assessment and criteria for identifying eligible women were often unclear.(12) At
115 the facility level, poor healthcare quality—attributed to various factors, such as insufficient

116 medicines and equipment for maternal and newborn care and lack of integration of ACS into
117 regular perinatal care—hinders appropriate ACS use.(9, 11) At the individual level, providers’
118 knowledge gaps in ACS use and identifying preterm labor hinder its proper use.(9, 14, 15).
119 Pregnant women, also at the individual level, may lack access to this intervention due to their
120 underlying socioeconomic constraints; among those who have access, their perceptions of risks
121 and benefits also affect ACS use.(9) Hence, untangling the complexity of factors affecting ACS
122 use is critical for identifying priority actions.

123 Appropriate settings for safe and effective ACS use are challenging to define. The WHO
124 recommends giving ACS when the following conditions are met: accurate GA assessment, a high
125 likelihood of imminent preterm labor, no clinical maternal infections, and adequate childbirth
126 and preterm newborn care available.(1) However, implementing some of these recommendations
127 in low-resource settings poses practical challenges, raising discussions in the global
128 community.(8, 16, 17) Facilities that can perform Comprehensive Emergency Obstetric and
129 Newborn Care (CEmONC) are considered appropriate settings for administering ACS.(1, 11)
130 Basic Emergency Obstetric and Newborn Care (BEmONC) includes a set of seven signal
131 functions; CEmONC includes all BEmONC services and adds two additional functions:
132 Cesarean section and blood transfusion.(18) This set of health services defines the capability of a
133 facility to manage obstetric and newborn emergencies (19, 20), and health facilities in LMICs are
134 designated as a BEmONC or CEmONC facility based on their capabilities.(18) It is important to
135 note that many pregnant women who present with obstetric emergencies and require CEmONC
136 services are likely to deliver preterm babies. While managing maternal emergencies, it is as
137 crucial for providers to take a holistic approach and simultaneously implement interventions that
138 improve preterm outcomes, such as administering antenatal corticosteroids. A study comparing

139 indices to measure facility readiness noted that the past performance of CEmONC signal
140 functions reflected a certain or minimally required level of inputs available and provider
141 competence in managing obstetric emergencies.(21) However, no studies have examined the
142 relationships between health facilities' abilities to perform CEmONC signal functions and ACS
143 utilization.

144 This study aimed to assess the complex relationships among ACS utilization, facility
145 characteristics, corticosteroid and ultrasound availability, structural readiness, and the past
146 performance of CEmONC signal functions.

147 **METHODS**

148 *Study sample*

149 We used Service Provision Assessment (SPA) health facility survey data from nine LMICs (ten
150 surveys).(22) Our sample included three countries from Asia (Afghanistan 2018-2019,
151 Bangladesh 2017-2018, Nepal 2021), one from the Caribbean (Haiti 2017-2018), and five from
152 sub-Saharan Africa (the Democratic Republic of Congo (DRC) 2017-2018, Ethiopia 2021-2022,
153 Malawi 2013-2014, Senegal 2018 and 2019, and Tanzania 2014-2015). We had previously
154 conducted a study examining antenatal corticosteroid utilization in LMICs using the same
155 data.(23) Most surveys employed a stratified random sampling strategy; some were national
156 censuses. Unlike other surveys, the Afghanistan 2018-2019 survey primarily sampled urban
157 hospitals. Since Senegal implemented continuous SPA over five consecutive years (24), we
158 merged the 2018 and 2019 Senegal SPA data to achieve a comparable sample size to other
159 surveys and to be consistent with our previous work.(23) The SPA questionnaire has five
160 instruments, of which this study used data from the inventory instrument. We restricted our
161 analyses to facilities that provided delivery services (normal delivery and/or Cesarean sections).

162 *Measures*

163 The primary outcome was recent ACS use at the facility level, defined as having administered
164 ACS within the past 3 months before the survey. Administering ACS within this timeframe was
165 believed to reflect the facility's functionality at the time of the survey.(18) We identified three
166 main groups of facility-level factors to explore their relationships with recent ACS use. First, we
167 included facility characteristics such as location (urban versus rural) and managing authority
168 types. Because surveys used different groupings for managing authority types, we developed a
169 standardized categorization with four groups (public, private for-profit, private not-for-
170 profit/mission or faith-based, and others) (**Supplemental Table 1**). Second, we identified 28
171 items essential for safe and effective ACS use based on the WHO recommendations, which
172 could be grouped into four major categories: equipment, diagnostics, medicines and
173 commodities, and guidelines (1); we used these items to develop facility structural readiness
174 (**Supplemental Table 2**). Based on the number of available items, we developed facility
175 readiness tertiles that were country-specific to account for the vastly different contexts and
176 survey years spanning from 2013 to 2021. A functional ultrasound was included separately
177 because access to ultrasound in early pregnancy is crucial for accurate GA dating. The measure
178 of a functional ultrasound was based on its availability in a health facility in general. The
179 availability of at least one valid corticosteroid (injectable betamethasone or dexamethasone) was
180 also included separately. However, we used its availability in the medicines for non-
181 communicable diseases as a proxy because SPA does not survey corticosteroid availability in the
182 maternal and newborn care section. We adopted the same approach as our previous study.(23)
183 Additionally, we constructed several binary variables that indicated having at least one medical
184 doctor, midwife, obstetrician/gynecologist, pediatrician, or specialist. Countries surveyed staff

185 types in various ways of grouping. All countries surveyed the availability of medical doctors and
186 midwives. Six countries (Afghanistan, Haiti, DRC, Malawi, Senegal, and Tanzania) assessed the
187 availability of specialists in general but not specifically obstetricians/gynecologists or
188 pediatricians. Conversely, three countries (Bangladesh, Nepal, and Ethiopia) collected data on
189 the availability of obstetricians/gynecologists and pediatricians but not specialists. We used this
190 data to construct a binary variable indicating at least one specialist. The development of staff
191 variables is detailed in **Supplemental Table 3**. Lastly, we included each CEmONC signal
192 function, defined as having ever performed each of them before the survey, in the model.

193 *Statistical analysis*

194 In reporting descriptive statistics, we presented the proportion of facilities that had used ACS
195 within the past three months before the survey by country and facility characteristics. We also
196 reported the proportion of facilities that had performed each CEmONC signal function. In
197 presenting outcome distribution across countries, we presented the median and range from eight
198 countries, excluding Afghanistan, because of its different sampling strategy. To assess factors
199 associated with recent ACS use, we conducted mixed-effect log binomial regressions to report
200 adjusted relative risks (RR), including country as a fixed effect and sub-national regions within
201 each country as random intercepts. We performed bivariate regressions that also included a fixed
202 effect of country and random intercepts of sub-national regions. Modified Poisson regressions
203 (with a robust standard error) were conducted to explore country-specific associations for each
204 country.(25) This approach was chosen to obtain effect measures of relative risks and ensure
205 model convergence with smaller sample sizes compared to the pooled regression models. We did
206 not include sub-national divisions as random intercepts in within-country regressions. All
207 analyses were performed using R.

208 RESULTS

209 This study included 6,183 facilities of nine LMICs from ten SPA surveys. Across eight countries
210 (excluding Afghanistan), about one-third of facilities (median 30.5%; range 14.6% to 89.6%)
211 were in urban areas, whereas most (99.4%) facilities in Afghanistan were urban (**Table 1**). Most
212 facilities were public (median 83.6%; range 43.1% to 91.6%), followed by private for-profit
213 facilities (median 9.8%; range 3.6% to 24.7%) and private not-for-profit/mission or faith-based
214 facilities (median 8.7%; range 0.8% to 27.2%). Staffing of specialized professionals was
215 generally suboptimal. Across eight countries, fewer than one-fifth or one-fifth of facilities had at
216 least one medical doctor (median 17.3%; range 6.1% to 76.5%) or midwife (median 20.2%;
217 range 7.7% to 95.9%). In Afghanistan, 39.6% of the facilities had at least one medical doctor,
218 and most (93.4%) had at least one midwife. For the three countries that assessed the availability
219 of obstetricians/gynecologists and pediatricians, fewer than 10% of the facilities had at least one
220 obstetrician/gynecologist (median 8.9%; range 7.5% to 16.7%) and pediatrician (median 7.5%;
221 range 5.1% to 12.5%). Similarly, only 9.1% (median; range 3.1% to 70.6%) of the facilities
222 among the six countries that surveyed specialists had at least one specialist.

223 *Recent ACS use.* The proportions of facilities that had used ACS within the past 3 months varied,
224 ranging from 4.0% in Tanzania to 27.4% in Ethiopia, with a median of 22.7% (**Table 2**).

225 Afghanistan had 59.4% of the facilities that used ACS recently. Recent ACS use also differed by
226 facility characteristics (**Table 2**). A larger proportion of urban facilities used ACS recently than
227 rural facilities (44.5% versus 21.1%). Facilities with injectable corticosteroids and a functional
228 ultrasound were more likely to use ACS in the past three months compared to those without. The
229 proportion of facilities that had recently used ACS increased by readiness tertile: 14.6% for the
230 lowest tertile, 21.9% for the middle, and 48% for the highest. Facilities with at least one medical

Table 1. Characteristics of surveys and facilities included in the analysis of 9 LMICs

Facility characteristics	Median (range) ¹	Country and survey year								
		Afghanistan 2018-2019 (n=101)	Bangladesh 2017-2018 (n=822)	Nepal 2021 (n=807)	Haiti 2017-2018 (n=362)	DRC 2017-2018 (n=1354)	Ethiopia 2021-2022 (n=650)	Malawi 2013-2014 (n=542)	Senegal 2018& 2019 (n=593)	Tanzania 2014-2015 (n=952)
Location										
Urban (%)	30.5% (14.6% - 89.6%)	100 (99.4%)	326 (21.9%)	485 (43.3%)	145 (40.0%)	293 (21.8%)	391 (39.0%)	82 (15.1%)	542 (89.6%)	278 (14.6%)
Managing authority type (%)										
Public	83.6% (43.1% - 91.6%)	14 (8.2%)	682 (83.6%)	631 (91.6%)	156 (43.1%)	823 (61.9%)	560 (91.3%)	356 (65.5%)	537 (85.3%)	692 (83.6%)
Private for-profit	9.8% (3.6% - 24.7%)	71 (71.4%)	104 (11.6%)	154 (7.5%)	89 (24.7%)	154 (17.9%)	75 (7.9%)	25 (4.9%)	37 (12.1%)	70 (3.6%)
Private not-for-profit/mission or faith-based	8.7% (0.8% - 27.2%)	16 (20.4%)	36 (4.9%)	22 (0.8%)	52 (14.3%)	377 (20.2%)	15 (0.9%)	148 (27.2%)	19 (2.6%)	180 (12.5%)
Others	0 % (0% - 17.9%)	0 (0%)	0 (0%)	0 (0%)	65 (17.9%)	0 (0%)	0 (0%)	13 (2.5%)	0 (0%)	10 (0.3%)
Staff (%)										
Has at least one medical doctor	17.3% (6.1% - 76.5%)	56 (39.6%)	344 (27.1%)	166 (7.1%)	277 (76.5%)	852 (31.1%)	431 (23.2%)	59 (10.8%)	138 (11.3%)	238 (6.1%)
Has at least one midwife	20.2% (7.7% - 95.9%)	97 (93.4%)	121 (8.6%)	176 (7.7%)	277 (76.5%)	233 (7.9%)	252 (9.3%)	520 (95.9%)	461 (74.3%)	577 (30.6%)
Has at least one obstetrician or gynecologist ²	8.9% (7.5% - 16.7%)	-	213 (16.7%)	196 (8.9%)	-	-	191 (7.5%)	-	-	-
Has at least one pediatrician ²	7.5% (5.1% - 12.5%)	-	164 (12.5%)	168 (7.5%)	-	-	144 (5.1%)	-	-	-
Has at least one specialist ²	9.1% (3.1% - 70.6%)	86 (70.6%)	-	-	165 (45.5%)	107 (3.3%)	-	31 (5.7%)	89 (12.5%)	133 (3.1%)

¹ Median and range were obtained from eight countries excluding Afghanistan.

² Only Bangladesh 2017-2018, Nepal 2021, and Ethiopia 2021-2022 surveyed the availability of obstetricians or gynecologists, and pediatricians. Other countries surveyed the availability of specialists but did not survey specific types of staff.

Table 2. Mixed effect log binomial regression models of recent antenatal corticosteroid utilization

	Proportion of facilities with recent ACS use (%) ¹	Bivariate regression ²			Multivariate regression ³		
		relative risk (RR)	95% CI	p-value	Adjusted relative risk (aRR)	95% CI	p-value
Country							
Afghanistan 2018-2019	59.4%	2.11	1.26 – 3.52	0.004	0.89	0.53 – 1.50	0.661
Nepal 2021	8.2%	0.45	0.28 – 0.71	0.001	0.34	0.22 – 0.51	<0.001
Haiti 2017-2018	23.6%	0.59	0.37 – 0.93	0.022	0.32	0.21 – 0.51	<0.001
DRC 2017-2018	22.2%	1.05	0.74 – 1.49	0.795	0.76	0.53 – 1.07	0.113
Ethiopia 2021-2022	27.4%	1.53	1.01 – 2.31	0.043	0.80	0.54 – 1.18	0.257
Malawi 2013-2014	21.5%	0.44	0.26 – 0.73	0.002	0.53	0.32 – 0.87	0.012
Senegal 2018 and 2019	23.4%	0.66	0.44 – 0.99	0.047	0.95	0.64 – 1.42	0.811
Tanzania 2014-2015	4.0%	0.35	0.24 – 0.51	<0.001	0.25	0.17 – 0.36	<0.001
Bangladesh 2017-2018	23.2%	<i>ref</i>			<i>ref</i>		
Facility characteristics							
<i>Location</i>							
Urban versus rural ⁴	44.5% versus 21.1%	3.09	2.77 – 3.45	<0.001	1.21	1.06 – 1.38	0.004
<i>Managing authority type</i>							
Public	28.0%	<i>ref</i>			<i>ref</i>		
Private for-profit	43.0%	1.51	1.32 – 1.74	<0.001	0.78	0.66 – 0.91	0.002
Private not-for-profit/faith or mission-based	37.8%	1.48	1.29 – 1.70	<0.001	0.85	0.73 – 0.99	0.039
Others	19.5%	1.00	0.59 – 1.68	0.995	0.99	0.58 – 1.69	0.975
Structural readiness							
Corticosteroid availability versus unavailability ⁵	45.1% versus 18.9%	2.72	2.43 – 3.04	<0.001	1.14	1.01 – 1.29	0.032
Ultrasound availability versus unavailability ⁵	60.9% versus 19.3%	5.00	4.48 – 5.57	<0.001	1.26	1.10 – 1.45	0.001
<i>Readiness tertile⁶</i>							
High	48.0%	7.52	6.37 – 8.89	<0.001	1.91	1.58 – 2.30	<0.001
Middle	21.9%	2.27	1.91 – 2.70	<0.001	1.23	1.03 – 1.48	0.021
Low	14.6%	<i>ref</i>			<i>ref</i>		
<i>Staffing⁷</i>							
At least one medical doctor versus no medical doctor ⁸	56.5% versus 13.2%	5.99	5.33 – 6.74	<0.001	1.43	1.22 – 1.67	<0.001
At least one midwife versus no midwife ⁸	38.8% versus 25.1%	3.17	2.84 – 3.55	<0.001	1.23	1.08 – 1.40	0.002
At least one specialist versus no specialist ⁸	61.8% versus 23.4%	4.37	3.91 – 4.90	<0.001	1.21	1.05 – 1.39	0.009
CEmONC signal functions⁹							
Ever provide parenteral antibiotics versus never	37.8% versus 6.1%	7.18	5.70 – 9.05	<0.001	1.48	1.15 – 1.90	0.002
Ever provide parenteral oxytocin versus never	33.1% versus 5.5%	8.73	5.80 – 13.14	<0.001	1.77	1.15 – 2.73	0.010
Ever provide parenteral anticonvulsants versus never	46.2% versus 11.5%	5.40	4.75 – 6.14	<0.001	1.65	1.43 – 1.91	<0.001
Ever perform assisted vaginal delivery versus never	37.1% versus 12.6%	3.44	2.91 – 4.06	<0.001	1.12	0.93 – 1.34	0.224
Ever perform manual removal of placenta versus never	38.2% versus 7.2%	5.62	4.57 – 6.91	<0.001	1.98	1.58 – 2.47	<0.001
Ever perform removal of retained products versus never	39.8% versus 11.8%	3.74	3.24 – 4.32	<0.001	1.39	1.19 – 1.63	<0.001
Ever perform neonatal resuscitation versus never	36.7% versus 4.4%	9.46	7.06 – 12.66	<0.001	2.62	1.93 – 3.55	<0.001
Ever perform Cesarean sections versus never	63.5% versus 13.1%	8.01	7.12 – 9.01	<0.001	1.85	1.53 – 2.24	<0.001
Ever provide blood transfusion versus never	63.8% versus 15.1%	6.69	5.99 – 7.47	<0.001	1.37	1.16 – 1.63	<0.001

¹ Recent ACS use was defined as using ACS within the past 3 months. For each country, the proportions were calculated considering facility sampling weight.

² Risk ratios (RR) were derived from bivariate regressions that included each independent variable separately, country fixed effects, and sub-national divisions as random intercepts.

³ Adjusted risk ratios (aRR) were derived from mixed effect log binomial regression model that included all independent variables, country fixed effects, and sub-national regions as random intercepts.

⁴ Rural is the reference level.

⁵ Unavailability is the reference level.

⁶ Readiness tertiles refer to country-specific readiness tertiles, calculated by the available numbers of equipment, diagnostics, medicines and commodities, and guidelines.

⁷ These binary variables indicate facilities having at least one medical doctor, midwife, or specialist, which were constructed based on the surveyed staff types for each SPA.

⁸ No medical doctor, no midwife, or no specialist is the reference level.

⁹ Facilities that never performed each CEmONC signal function were viewed as the reference level

231 doctor, midwife, or specialist were more likely to administer ACS recently than those without:
232 56.5% versus 13.2%, 38.8% versus 25.1%, 61.8% versus 23.4%, respectively. In addition, higher
233 proportions of facilities that had provided any of the CEmONC services used ACS recently than
234 those that had never performed the signal function.

235 *CEmONC signal functions past performance.* One-fifth of the facilities (19.0%, median of eight
236 countries) had ever performed all nine CEmONC signal functions, compared to two-fifths
237 (40.6%) in Afghanistan. Across eight countries and among nine signal functions, Cesarean
238 sections and the provision of blood transfusions were performed in the smallest proportion of
239 facilities since only CEmONC facilities were designated for these two services. Among seven
240 BEmONC signal functions, the provision of parenteral anticonvulsant was performed in the
241 smallest proportion of facilities (median 37.6%), while oxytocin administration was performed in
242 the largest proportion (median 94.3%) (**Figure 1**). Ethiopia was the only country among the eight
243 countries where more than 80% of the facilities had performed each BEmONC signal function.

244 **Figure 1.** Proportion of facilities that have performed nine Comprehensive Emergency Obstetric
245 and Newborn Care (CEmONC) signal functions

246 *Factors affecting recent ACS use.* **Table 2** details the results of mixed-effect log binomial
247 regressions, showing that facility characteristics, structural readiness, and past performance of
248 CEmONC are associated with recent ACS use. Urban facilities had 21% higher recent ACS use
249 than rural facilities (RR 1.21, 95% CI 1.06–1.39). Private for-profit facilities and private not-for-
250 profit facilities, compared to public facilities, were associated with lower recent ACS use,
251 although both types showed higher recent ACS use in bivariate regressions. The availability of
252 injectable corticosteroids and ultrasound were associated with increased recent ACS use by 14%

253 (RR 1.14, 95% CI 1.01–1.29) and 26% (RR 1.26, 95% CI 1.10–1.45), respectively. Facilities in
254 the highest readiness tertile had 91% higher recent ACS use than those in the lowest (RR 1.91,
255 95% CI 1.58–2.30). Staffing types affected recent ACS use: facilities with at least one medical
256 doctor, midwife, or specialist had increased recent ACS use by 43% (RR 1.43, 95% CI 1.22–
257 1.67), 23% (RR 1.23, 95% CI 1.08 to 1.40), and 21% (RR 1.21, 95%CI 1.05–1.39), respectively.
258 Lastly, past performance of each CEmONC signal function, except for assisted vaginal
259 deliveries, was significantly associated with more recent ACS use, with performing neonatal
260 resuscitation having the largest effect (RR 2.62, 95%CI 1.93–3.56). Country-specific regressions
261 were detailed in **Supplemental Table 4**.

262 **DISCUSSION**

263 Our study showed the complex relationships between recent ACS utilization and facility-level
264 factors. We found that recent ACS use was significantly higher in urban facilities, facilities with
265 injectable corticosteroids and ultrasound available, facilities with the highest level of readiness,
266 and facilities that had performed CEmONC services.

267 A consistent corticosteroid stock is fundamental for promoting ACS use.(26, 27) Our previous
268 work found that only one-fourth of the facilities that provided antenatal care or delivery services
269 in the same eight countries (excluding Afghanistan) had injectable corticosteroids available.(23)
270 Interestingly, this study found a relatively small effect of corticosteroid availability (RR 1.14).
271 As we used the availability of corticosteroids under the medicines for non-communicable
272 diseases as a proxy, this approach might have overestimated their availability in maternal care.
273 Thus, the effect size, while still statistically significant, is not as large as expected. The
274 phenomenon might be explained by the idea that corticosteroid unavailability only partially
275 contributed to the barrier to proper ACS use. In other words, while the availability of

276 corticosteroids is essential, it does not guarantee their use. Our previous study also revealed the
277 gap between corticosteroid availability and ACS use.(23) We suspect that the effect of
278 corticosteroid availability might be offset by other factors, such as providers' insufficient
279 knowledge. Providers play a critical role in effective ACS utilization, including their awareness
280 and knowledge of ACS, abilities to identify eligible women, and their perceived risks and
281 benefits of ACS.(14, 15, 26, 28, 29) Similarly, the concern about the gap between availability
282 and utilization also applies to facility readiness, meaning that high structural readiness does not
283 always translate into good clinical practices; for example, the volume of delivery service of a
284 facility is related to its provision of services for managing obstetric emergencies.(30) To
285 triangulate factors affecting ACS use, by summarizing previous evidence, we proposed a
286 framework for effective and safe ACS use at four levels (**Figure 2**).

287 **Figure 2.** Framework for safe and effective antenatal corticosteroid utilization at four levels

288 While we found an association between ultrasound availability and recent ACS use, the effect
289 size is relatively small, and the interpretation requires caution. First, ultrasound in early
290 pregnancy, the gold standard for accurate GA dating, is uncommon in low-resource countries.
291 Although its use is increasing in these countries (31), our previous work showed that only 7.3%
292 of facilities that provided antenatal care or delivery services in eight LMICs had a functional
293 ultrasound at the time of the survey.(23) A Bangladesh household survey of 700 women found
294 that only 11% received an ultrasound examination in the first trimester.(32) Another critical
295 point is that many women in LMICs initiate their antenatal care late (33, 34), resulting in missed
296 opportunities. The prevalence of early antenatal care visits, defined as initiating before 14 weeks
297 of gestation, was only 24.0% in LMICs versus 81.9% in high-income countries.(33) The limited
298 ultrasound availability and late presentation to antenatal care might partly explain the small

299 effect size in our findings. Additionally, the ultrasound measurement we used only reflected its
300 availability at the time of the survey, which may not fully represent its availability in women’s
301 first antenatal care visits, whether in the same facility or another.

302 Notably, this study identified strong associations between CEmONC signal functions and recent
303 ACS use. There are a few potential explanations. First, CEmONC signal functions are meant to
304 manage obstetric emergencies, which often involve a high likelihood of preterm labor. In these
305 cases, providers should adopt a comprehensive approach to both save mothers’ lives and improve
306 preterm newborn outcomes, including ACS administration to eligible women. For example,
307 studies have demonstrated the benefits of administering ACS to women with severe
308 preeclampsia.(35, 36) Second, this finding highlights the importance of provider knowledge,
309 skills, and competence. The effect sizes for some CEmONC signal functions (RR 2.62 for
310 neonatal resuscitation, RR 1.98 for performing manual removal of placenta, and 1.85 for
311 performing Cesarean sections) are much larger than that for corticosteroid availability (RR 1.14).
312 In other words, by controlling for all other factors, facilities with providers who have performed
313 neonatal resuscitations are much more likely to administer ACS. This finding suggests that past
314 performance of CEmONC signal functions reflects two critical aspects: first, providers’
315 knowledge, skills, and competence to perform the services, and second, the availability of a
316 minimal level of medicines and equipment.(21) These two are crucial for delivering effective
317 care; missing either will not work. Our findings have strong policy implications. Policymakers
318 should prioritize provider training in emergent obstetric care while improving facility readiness
319 and creating environments that encourage good clinical practice because in-service training alone
320 does not deliver long-lasting effects.(37)

321 Our study has a few limitations. First, the countries in our sample differed in many aspects.(23)

322 For example, national guidelines about ACS use vary. Some countries, such as Tanzania and

323 Ethiopia, recommend administering ACS at the primary level of care, followed by referrals.(38-

324 40) We recommend careful interpretations in any attempt to compare across countries. Second,

325 there is a temporal discrepancy between corticosteroid availability and recent ACS use, with the

326 former measured at the time of the survey and the latter defined as having provided ACS in the

327 past 3 months before the survey. In addition, ACS utilization in the past 3 months does not

328 represent the appropriateness of ACS use, meaning that the correct doses are given to eligible

329 pregnant women at the right times. Third, we are aware of the collinearity between some

330 independent variables in the regressions. For instance, facilities in the highest readiness tertile

331 are likely to have the equipment, medicines, or staff required for CEmONC signal functions.

332 This study confirmed the complexity of factors affecting ACS utilization in LMICs. While

333 corticosteroid availability is fundamental, providers' knowledge and skills – reflected by the past

334 performance of CEmONC services in our findings–affect safe and effective ACS administration.

335 Policymakers should examine factors contributing to low ACS use at various levels and identify

336 strategies to promote the implementation of this life-saving intervention.

337 **Disclosure of relationships and activities:** All authors have completed the ICMJE uniform

338 disclosure form at www.icmje.org/coi_disclosure.pdf and declared no support from any

339 organization for submitted work; no financial relationships with any organization that might have

340 an interest in the submitted work in the previous three years; no other relationships or activities

341 that could appear to have influenced the submitted work.

342 **Ethical approval:** This study was determined by the George Washington University Committee
343 on Human Research, Institutional Review Board to be research that is exempt from IRB review
344 (IRB# NCR235271).

345 **Author contributions:** WCY, CA, VYF, and ESR conceptualized and designed the study and
346 proposed an analysis plan. WCY conducted the analysis. CA, VYF, NBA, FMAA, and ESR
347 provided inputs to the analysis results and suggested additional analyses. NBA reviewed the
348 statistical codes and provided feedback. WCY, CA, and ESR drafted the manuscript. NBA and
349 FMAA provided insights based on their expertise about the context and suggested areas for
350 discussion. All authors critically reviewed the manuscript, made edits, and approved the final
351 version of the manuscript for submission.

352 **Funding and sponsorship:** This study was not funded.

353 **Supporting information:** Supplementary file


REFERENCES

1. The World Health Organization. 2022 WHO recommendations on ACS to improve preterm birth outcomes. 2022.
2. Reddy UM, Deshmukh U, Dude A, Harper L, Osmundson SS. Society for Maternal-Fetal Medicine Consult Series #58: Use of antenatal corticosteroids for individuals at risk for late preterm delivery: Replaces SMFM Statement #4, Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery, August 2016. *American journal of obstetrics and gynecology*. 2021;225(5):B36-b42.
3. Norman J, Shennan A, Jacobsson B, Stock SJ, Birth FWGfP. FIGO good practice recommendations on the use of prenatal corticosteroids to improve outcomes and minimize harm in babies born preterm. *Int J Gynaecol Obstet*. 2021;155(1):26-30.
4. El-Sayed YY, Borders AEB, Gyamfi-Bannerma C. ACOG committee opinion, Antenatal Corticosteroid Therapy for Fetal Maturation The American College of Obstetricians and Gynecologists. 2017;130(2):e102-e9.
5. McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev*. 2020;12(12):Cd004454.
6. Chawanpaiboon S, Vogel JP, Moller AB, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. *The Lancet Global health*. 2019;7(1):e37-e46.
7. The World Health Organization. Born too soon: decade of action on preterm birth. 2023.
8. Hall M, Valencia CM, Soma-Pillay P, Luyt K, Jacobsson B, Shennan A. Effective and simple interventions to improve outcomes for preterm infants worldwide: The FIGO PremPrep-5 initiative. *Int J Gynaecol Obstet*. 2024;165(3):929-35.
9. Zahroh RI, Hazfiarini A, Eddy KE, Vogel JP, Tunçalp Ö, Minckas N, et al. Factors influencing appropriate use of interventions for management of women experiencing preterm birth: A mixed-methods systematic review and narrative synthesis. *PLoS medicine*. 2022;19(8):e1004074.
10. Aleman A, Cafferata ML, Gibbons L, Althabe F, Ortiz J, Sandoval X, et al. Use of antenatal corticosteroids for preterm birth in Latin America: providers knowledge, attitudes and practices. *Reprod Health*. 2013;10:4.
11. Liu G, Segrè J, Gülmezoglu A, Mathai M, Smith JM, Hermida J, et al. Antenatal corticosteroids for management of preterm birth: a multi-country analysis of health system bottlenecks and potential solutions. *BMC pregnancy and childbirth*. 2015;15 Suppl 2(Suppl 2):S3.
12. Greensides D, Robb-McCord J, Noriega A, Litch JA. Antenatal Corticosteroids for Women at Risk of Imminent Preterm Birth in 7 sub-Saharan African Countries: A Policy and Implementation Landscape Analysis. *Global health, science and practice*. 2018;6(4):644-56.
13. The World Health Organization. The WHO Model List of Essential Medicines 23rd list 2023.

14. Levison J, Nanthuru D, Chiudzu G, Kazembe PN, Phiri H, Ramin SM, et al. Qualitative assessment of attitudes and knowledge on preterm birth in Malawi and within country framework of care. *BMC pregnancy and childbirth*. 2014;14:123.
15. Antony KM, Levison J, Suter MA, Raine S, Chiudzu G, Phiri H, et al. Qualitative assessment of knowledge transfer regarding preterm birth in Malawi following the implementation of targeted health messages over 3 years. *International journal of women's health*. 2019;11:75-95.
16. Townsend R, Calvert C. Antenatal corticosteroids in adequately equipped facilities in low-resource settings. *The Lancet Global health*. 2022;10(10):e1379-e80.
17. Sultana S, Vogel JP, Oladapo OT. The efficacy of antenatal corticosteroids to improve preterm newborn outcomes in low-resource countries: Are we there yet? *BJOG : an international journal of obstetrics and gynaecology*. 2023.
18. The World Health Organization. *Monitoring Emergency Obstetric Care: a Handbook*. 2009.
19. Otolorin E, Gomez P, Currie S, Thapa K, Dao B. Essential basic and emergency obstetric and newborn care: from education and training to service delivery and quality of care. *Int J Gynaecol Obstet*. 2015;130 Suppl 2:S46-53.
20. Campbell OM, Graham WJ. Strategies for reducing maternal mortality: getting on with what works. *Lancet (London, England)*. 2006;368(9543):1284-99.
21. Stierman EK, Ahmed S, Shiferaw S, Zimmerman LA, Creanga AA. Measuring facility readiness to provide childbirth care: a comparison of indices using data from a health facility survey in Ethiopia. *BMJ Glob Health*. 2021;6(10).
22. The DHS program. The Demographic and Health Surveys, The Service Provision Assessment USAID; [Available from: <https://dhsprogram.com/methodology/Survey-Types/SPA.cfm>].
23. Yang W-C, Arsenault C, Fan VY, Leslie HH, Farooq F, Pembe AB, et al. Antenatal corticosteroids for pregnant women at risk of preterm labor in low- and middle-income countries: utilization and facility readiness. *medRxiv*. 2024:2024.07.31.24310863.
24. The DHS program. *Continuous Service Provision Assessment*.
25. Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. *American Journal of Epidemiology*. 2004;159(7):702-6.
26. Kaplan HC, Sherman SN, Cleveland C, Goldenhar LM, Lannon CM, Bailit JL. Reliable implementation of evidence: a qualitative study of antenatal corticosteroid administration in Ohio hospitals. *BMJ quality & safety*. 2016;25(3):173-81.
27. Smith JM, Gupta S, Williams E, Brickson K, Ly Sotha K, Tep N, et al. Providing antenatal corticosteroids for preterm birth: a quality improvement initiative in Cambodia and the Philippines. *International journal for quality in health care : journal of the International Society for Quality in Health Care*. 2016;28(6):682-8.
28. Leviton LC, Baker S, Hassol A, Goldenberg RL. An exploration of opinion and practice patterns affecting low use of antenatal corticosteroids. *American journal of obstetrics and gynecology*. 1995;173(1):312-6.
29. Mc Goldrick EL, Crawford T, Brown JA, Groom KM, Crowther CA. Identifying the barriers and enablers in the implementation of the New Zealand and Australian Antenatal Corticosteroid Clinical Practice Guidelines. *BMC health services research*. 2016;16(1):617.

30. Kruk ME, Leslie HH, Verguet S, Mbaruku GM, Adanu RMK, Langer A. Quality of basic maternal care functions in health facilities of five African countries: an analysis of national health system surveys. *The Lancet Global health*. 2016;4(11):e845-e55.
31. Stewart KA, Navarro SM, Kambala S, Tan G, Poondla R, Lederman S, et al. Trends in Ultrasound Use in Low and Middle Income Countries: A Systematic Review. *International journal of MCH and AIDS*. 2020;9(1):103-20.
32. Siddique AB, Perkins J, Mazumder T, Haider MR, Banik G, Tahsina T, et al. Antenatal care in rural Bangladesh: Gaps in adequate coverage and content. *PLoS One*. 2018;13(11):e0205149.
33. Moller AB, Petzold M, Chou D, Say L. Early antenatal care visit: a systematic analysis of regional and global levels and trends of coverage from 1990 to 2013. *The Lancet Global health*. 2017;5(10):e977-e83.
34. Gebresilassie B, Belete T, Tilahun W, Berhane B, Gebresilassie S. Timing of first antenatal care attendance and associated factors among pregnant women in public health institutions of Axum town, Tigray, Ethiopia, 2017: a mixed design study. *BMC pregnancy and childbirth*. 2019;19(1):340.
35. Briceño-Pérez C, Reyna-Villasmil E, Vigil-De-Gracia P. Antenatal corticosteroid therapy: Historical and scientific basis to improve preterm birth management. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2019;234:32-7.
36. Magann EF, Haram K, Ounpraseuth S, Mortensen JH, Spencer HJ, Morrison JC. Use of antenatal corticosteroids in special circumstances: a comprehensive review. *Acta obstetrica et gynecologica Scandinavica*. 2017;96(4):395-409.
37. Arsenault C, Rowe SY, Ross-Degnan D, Peters DH, Roder-DeWan S, Kruk ME, et al. How does the effectiveness of strategies to improve healthcare provider practices in low-income and middle-income countries change after implementation? Secondary analysis of a systematic review. *BMJ quality & safety*. 2022;31(2):123-33.
38. Ministry of Health and Social Welfare the United Republic of Tanzania. Administration of Antenatal Corticosteroids in Pre-Term Labour. 2015.
39. Ministry of Health Ethiopia. Obstetrics Management Protocol for Hospitals. 2021.
40. Ministry of Health Ethiopia. Obstetrics Management Protocol for Health Centers. 2021.

Proportion of facilities that have performed CEMONC signal functions by country



AFG18: Afghanistan 2018-2019; BD17: Bangladesh 2017-2018; NP21: Nepal 2021; HT17: Haiti 2017-2018; DRC17: the Democratic Republic of Congo 2017-2018; ET21: Ethiopia 2021-2022; MW13: Malawi 2013-2014; SN1819: Senegal 2018 and 2019; TZ14: Tanzania 2014-2015; median*: median across eight countries except Afghanistan

Figure 1




Figure2